Zhaoming Li1, Yue Song1, Mingzhi Zhang1, Yiming Wei1,2, Hang Ruan1,2. 1. Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China. 2. State Key Laboratory of Esophageal Cancer Prevention & Treatment and Henan Key Laboratory for Esophageal Cancer Research, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
Abstract
Objective: T-cell lymphoblastic lymphoma (T-LBL) is an aggressive neoplasm of precursor T cells, however, detailed genome-wide sequencing of large T-LBL cohorts has not been performed due to its rarity. The purpose of this study was to identify putative driver genes in T-LBL. Methods: To gain insight into the genetic mechanisms of T-LBL development, we performed whole-exome sequencing on 41 paired tumor-normal DNA samples from patients with T-LBL. Results: We identified 32 putative driver genes using whole-exome sequencing in 41 T-LBL cases, many of which have not previously been described in T-LBL, such as Janus kinase 3 (JAK3), Janus kinase 1 (JAK1), Runt-related transcription factor 1 (RUNX1) and Wilms' tumor suppressor gene 1 (WT1). When comparing the genetic alterations of T-LBL to T-cell acute lymphoblastic leukemia (T-ALL), we found that JAK-STAT and RAS pathway mutations were predominantly observed in T-LBL (58.5% and 34.1%, respectively), whereas Notch and cell cycle signaling pathways mutations were more prevalent in T-ALL. Notably, besides notch receptor 1 (NOTCH1), mutational status of plant homeodomain (PHD)-like finger protein 6 (PHF6) was identified as another independent factor for good prognosis. Of utmost interest is that co-existence of PHF6 and NOTCH1 mutation status might provide an alternative for early therapeutic stratification in T-LBL. Conclusions: Together, our findings will not only provide new insights into the molecular and genetic mechanisms of T-LBL, but also have tangible implications for clinical practice.
Objective: T-cell lymphoblastic lymphoma (T-LBL) is an aggressive neoplasm of precursor T cells, however, detailed genome-wide sequencing of large T-LBL cohorts has not been performed due to its rarity. The purpose of this study was to identify putative driver genes in T-LBL. Methods: To gain insight into the genetic mechanisms of T-LBL development, we performed whole-exome sequencing on 41 paired tumor-normal DNA samples from patients with T-LBL. Results: We identified 32 putative driver genes using whole-exome sequencing in 41 T-LBL cases, many of which have not previously been described in T-LBL, such as Janus kinase 3 (JAK3), Janus kinase 1 (JAK1), Runt-related transcription factor 1 (RUNX1) and Wilms' tumor suppressor gene 1 (WT1). When comparing the genetic alterations of T-LBL to T-cell acute lymphoblastic leukemia (T-ALL), we found that JAK-STAT and RAS pathway mutations were predominantly observed in T-LBL (58.5% and 34.1%, respectively), whereas Notch and cell cycle signaling pathways mutations were more prevalent in T-ALL. Notably, besides notch receptor 1 (NOTCH1), mutational status of plant homeodomain (PHD)-like finger protein 6 (PHF6) was identified as another independent factor for good prognosis. Of utmost interest is that co-existence of PHF6 and NOTCH1 mutation status might provide an alternative for early therapeutic stratification in T-LBL. Conclusions: Together, our findings will not only provide new insights into the molecular and genetic mechanisms of T-LBL, but also have tangible implications for clinical practice.
Authors: S T Balbach; O Makarova; B R Bonn; M Zimmermann; M Rohde; I Oschlies; W Klapper; C Rössig; B Burkhardt Journal: Leukemia Date: 2015-07-28 Impact factor: 11.528
Authors: Agnieszka A Wendorff; S Aidan Quinn; Marissa Rashkovan; Chioma J Madubata; Alberto Ambesi-Impiombato; Mark R Litzow; Martin S Tallman; Elisabeth Paietta; Maddalena Paganin; Giuseppe Basso; Julie M Gastier-Foster; Mignon L Loh; Raul Rabadan; Pieter Van Vlierberghe; Adolfo A Ferrando Journal: Cancer Discov Date: 2018-12-19 Impact factor: 39.397
Authors: E Waanders; V H J van der Velden; C E van der Schoot; F N van Leeuwen; S V van Reijmersdal; V de Haas; A J Veerman; A Geurts van Kessel; P M Hoogerbrugge; R P Kuiper; J J M van Dongen Journal: Leukemia Date: 2010-11-19 Impact factor: 11.528
Authors: Pieter Van Vlierberghe; Teresa Palomero; Hossein Khiabanian; Joni Van der Meulen; Mireia Castillo; Nadine Van Roy; Barbara De Moerloose; Jan Philippé; Sara González-García; María L Toribio; Tom Taghon; Linda Zuurbier; Barbara Cauwelier; Christine J Harrison; Claire Schwab; Markus Pisecker; Sabine Strehl; Anton W Langerak; Jozef Gecz; Edwin Sonneveld; Rob Pieters; Elisabeth Paietta; Jacob M Rowe; Peter H Wiernik; Yves Benoit; Jean Soulier; Bruce Poppe; Xiaopan Yao; Carlos Cordon-Cardo; Jules Meijerink; Raul Rabadan; Frank Speleman; Adolfo Ferrando Journal: Nat Genet Date: 2010-03-14 Impact factor: 38.330
Authors: A Renneville; S Kaltenbach; E Clappier; S Collette; J-B Micol; B Nelken; P Lepelley; N Dastugue; Y Benoît; Y Bertrand; C Preudhomme; H Cavé Journal: Leukemia Date: 2009-10-22 Impact factor: 11.528